Innovative EDV Therapy Targets Brain Cancer
On May 1, 2026, EnGeneIC Limited announced the dosing of the first patient in its clinical trial for EGFR-targeted EDV™ therapy at Westmead Hospital in Sydney. This trial focuses on patients with recurrent glioblastoma multiforme, a severe and currently incurable brain cancer.
Dr. Mark Wong, a Medical Oncologist at Westmead Hospital, is leading the trial. It aims to assess the safety and effectiveness of this innovative therapy for patients who have few treatment options left. Recruitment will soon include The Kinghorn Cancer Centre and expand to clinical sites in Singapore.
According to Dr. Mark Wong, “This first patient dosed milestone is a critical step forward for patients with recurrent glioblastoma, who typically have very limited treatment options once standard therapies have failed.”
In the clinical context, recurrent glioblastoma remains highly resistant to conventional chemotherapy and immunotherapy. EGFR-targeted EDVs offer a novel approach by combining targeted intracellular drug delivery with immune activation in a disease where both effective tumour penetration and immune engagement have historically been major challenges.
How EDV Therapy Works
EDV therapy uses nanocell-based particles engineered to bind to the epidermal growth factor receptor (EGFR). This receptor is frequently over-expressed in glioblastoma. The particles carry doxorubicin, a chemotherapy agent, and α-galactosyl ceramide, an immune-modulating adjuvant. The goal is to kill tumour cells and trigger a broad immune response.
Dr. Jennifer MacDiarmid, Joint CEO and Director of EnGeneIC, commented that the trial builds on promising results seen in compassionate case studies with recurrent glioblastoma patients. These results support the advancement of the EGFR-targeted EDV therapy into a formal clinical trial.
The dual-payload design of the therapy is intended to directly target EGFR-expressing tumours while activating the immune system. This approach may convert an immunologically ‘cold’ tumour into one that the immune system can recognise and attack.
Patient recruitment is expected to continue across Australian and Singaporean sites in accordance with the trial protocol and applicable regulatory approvals. This development provides hope for new therapeutic options in a disease with serious unmet medical needs.
The investigational treatment consists of EGFR-targeted EnGeneIC Dream Vectors (EDVs) — bacterially derived, nanocell-based particles engineered to selectively bind to epidermal growth factor receptor (EGFR), which is frequently over-expressed in glioblastoma. The EDVs are loaded with the chemotherapeutic agent doxorubicin and the immune-modulating adjuvant α-galactosyl ceramide (α-GalCer).
Dr. Jennifer MacDiarmid also noted, “This clinical trial builds on spectacular overall survival outcomes currently observed in Compassionate Case Study patients with recurrent glioblastoma who had exhausted all available treatment options.”
Last updated: 29 June 2026, 12:16 pm
